Zinbryta (Abbvie)


Welcome to the PulseAid listing for the Zinbryta drug offered from Abbvie. This Interleukin 2 Receptor Antagonists [MoA],Interleukin 2 Receptor-directed Antibody Interactions [MoA],Interleukin-2 Receptor Blocking Antibody [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view the details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Abbvie
NON-PROPRIETARY NAME: Daclizumab
SUBSTANCE NAME: DACLIZUMAB
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Interleukin 2 Receptor Antagonists [MoA],Interleukin 2 Receptor-directed Antibody Interactions [MoA],Interleukin-2 Receptor Blocking Antibody [EPC]
ROUTE: SUBCUTANEOUS
DOSAGE FORM: INJECTION, SOLUTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2016-05-27
END MARKETING DATE: 0000-00-00


Zinbryta HUMAN PRESCRIPTION DRUG Details:

Item DescriptionZinbryta from Abbvie
LABELER NAME: Abbvie
DEA SCHEDULE:
ACTIVE STRENGTH: 150(mg/mL)
START MARKETING DATE: 2016-05-27
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0074-0033_78f3fa21-13f6-4f2e-b6bd-d786270d1a7d
PRODUCT NDC: 0074-0033
APPLICATION NUMBER: BLA761029

Other DACLIZUMAB Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
AbbvieZinbryta